Trials / Unknown
UnknownNCT06098898
Safety and Efficacy of NK510 to Treat Gastric Cancer
Exploratory Study of NK510 Cell Therapy Combined With Monoclonal Antibody in the Treatment of Recurrent and Refractory Advanced Gastric Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NK510 | NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles. |
| DRUG | Tislelizumab，atezolizumab or Trastuzumab | Administer according to the instructions. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2023-10-25
- Last updated
- 2023-10-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06098898. Inclusion in this directory is not an endorsement.